

sequence of SEQ ID NO. 1.

16. The method according to claim 12, wherein the at least one bioactive polypeptide has the amino acid sequence of SEQ ID NO. 1.

17. The method according to claim 12, wherein the at least one bioactive polypeptide is a-peptiferon, albeferon, albebetin or a mixture thereof.

18. A method for treating undesirable side effects during organ or tissue transplantation, or for treating lymphoma, leukemias, myelomas, adenocarcinomas, an autoimmune disease, or a chronic inflammatory disease comprising administering to a subject in need thereof an effective amount of a composition according to claim 6.--

---

REMARKS

The amendment of claim 2 by substitution of claim 5 is not a narrowing amendment, but rather clarifies what is intended to be the claimed subject matter. New claims 6 – 18 are added to more completely claim the invention with terms of varying scope.

The limitation "8-mer" finds description in specification at, for example, page 12, line 27.

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a Sequence Listing to be inserted into the specification as indicated above. The Sequence Listing in no way introduces new matter into the specification.

Also submitted herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a disk copy of the Sequence Listing. The disk copy of the Sequence Listing, file "0933-0149P.ST25", is identical to the paper copy, except that it lacks formatting.

Attached hereto is a marked up version of the changes made to the specification and claims by this amendment.

The sequence of the Sequence Listing is from the table in Claim 2 of the application. No new matter is added by the addition of the sequence of the Sequence Listing.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future submissions, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *Gerald M. Murphy, Jr.* # 36,623

GERALD M. MURPHY, JR.  
Reg. No. 28,977

P.O. Box 747  
Falls Church, VA 22040-07478000

(703) 205-GMM/MAA/KW

0933-0149P

Attachments: Paper and Disk Copy of Sequence Listing  
Copy of Notice to Comply  
Marked Up Version of Changes Made to The Specification and Claims

MARKED UP VERSION OF CHANGES MADE TO THE SPECIFICATION AND CLAIMS

(amended)1. ~~AAny drug~~ composition ~~consisting of comprising~~ immunosuppressants, cyclosporins, FK506, or rapamycin and at least one ~~the~~ bioactive peptides ~~corresponding to the high-affinity binding/anti-lymphoproliferative site of interferons a,b,w,t, or recombinant proteins carrying one or more of the sequences corresponding to the structures of the bioactive peptides corresponding to the high-affinity binding/anti-lymphoproliferative site of the said interferons for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation or during treatment of cancers such as lymphomas, leukemias, myelomas, adenocarcinomas, autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis, myasthenia gravis, lupus erythematosus, uveitis, hyperproliferative diseases, such as psoriasis vulgaris, wherein cyclosporins, FK506 or rapamycin can be exploited.~~

(amended)3. The ~~c~~Compositions according to Claim 1 ~~consisting of comprising~~ at one immunosuppressants cyclosporins, FK506 or rapamycin, and at least one recombinant proteins ~~comprising~~carrying one or more of the sequences of SEQ ID NO 1 or a variant thereof that is SEQ ID NO 2, such that at up to three amino acids of SEQ ID NO 1 are substituted.~~corresponding to the peptide variation of Claim 2.~~

(amended)4. The ~~c~~Compositions according to Claim 5 wherein the~~2~~ ~~consisting of immunosuppressants cyclosporins, FK506 and rapamycin, and the bioactive peptides wherein the active~~ at least one ~~peptides~~ is~~are~~ genetically or chemically modified or genetically or chemically or physically bound to a small-molecular or macromolecular substance ~~for the aim of increasing the stabilityies of the~~ at least one peptides in physiological conditions or for regulating the bioavailability of the at least one ~~said~~ peptide.

Claim 2 is canceled

Claims 5-18 are newly added.

The Sequence Listing is appended to the specification.